The University of Virginia is conducting a clinical research study for adults ages 18 and over who have a disease, called light chain (AL) amyloidosis, in which protein builds up through your body. The purpose of the study is to evaluate the safety and tolerability of venetoclax, MLN9708 (ixazomib citrate), and dexamethasone when used in combination for patients who have been previously treated for this disease but did not respond or have progressed. The study will test different doses of the drug to see which dose is safer for people. There will be up to 24 people taking part in the dose escalation stage of this study, and up to 9 people taking part in the dose expansion stage of the study, with some patients taking part in both stages of the study. Your doctor will tell you which part of the study you will participate in.
You will receive study treatment until your disease progresses. After you finish study treatment, your doctor will continue to follow your condition and watch you for side effects every 1-3 months through clinic visits and phone calls.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04847453
uvacancertrials@hscmail.mcc.virginia.edu
Compensation: You will not be paid for your participation in the study.
No Compensation